Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

Specimen Handling 146pembrolizumab 118Magnetic Resonance Spectroscopy 117Cyclophosphamide 113Biopsy 96fludarabine 88Nivolumab 52Carboplatin 51Cisplatin 47Gemcitabine 46Radiotherapy 41venetoclax 40Cetuximab 40fludarabine phosphate 39Paclitaxel 39Ipilimumab 34atezolizumab 33Fluorouracil 33Bevacizumab 32Oxaliplatin 27Leucovorin 27Dexamethasone 26durvalumab 25X-Rays 25Irinotecan 25Radiation 24Cytarabine 23Azacitidine 23Injections 22Temozolomide 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Gemtuzumab × 90 days × Clear all
NCT04915612 2026-05-20

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
1 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03900949 2026-05-15

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
21 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡